Medtronic, St. Jude Will Not Take CRT Market Share, Guidant Vows
This article was originally published in The Gray Sheet
Executive Summary
Guidant expects to maintain its 38% share of the cardiac resynchronization therapy (CRT) market in the second half of 2004 despite a recent Medtronic launch and emerging competition from St. Jude
You may also be interested in...
St. Jude Expects To Take More CRT Share From Guidant Than Medtronic
Guidant's share of the cardiac resynchronization therapy (CRT) market is more vulnerable than that of Medtronic, according to St. Jude Medical CFO John Heinmiller
St. Jude Expects To Take More CRT Share From Guidant Than Medtronic
Guidant's share of the cardiac resynchronization therapy (CRT) market is more vulnerable than that of Medtronic, according to St. Jude Medical CFO John Heinmiller
St. Jude Commences Simultaneous Epic HF, Atlas+ HF CRT-D Launches
St. Jude Medical's entry into the cardiac resynchronization therapy (CRT) market will be supported by a 20% sales force expansion, from roughly 1,000 to 1,200 people this year